EUVIMEDEUVIMED entdecken
Crossref

Survival Impact of Glucocorticoid Administration for Adverse Events During Immune Checkpoint Inhibitor Combination Therapy in Patients with Previously Untreated Advanced Renal Cell Carcinoma

Maki Yoshino, Hiroki Ishihara iD, Yuki Nemoto, Shinsuke Mizoguchi, Takashi Ikeda, Takayuki Nakayama, Hironori Fukuda, Kazuhiko Yoshida, Junpei Iizuka, Hiroaki Shimmura, Yasunobu Hashimoto, Tsunenori Kondo und 1 weitere

Targeted Oncology · 2024

DOI: 10.1007/s11523-024-01069-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Targeted Oncology, 2024. Verfasst von Maki Yoshino und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Immune Checkpoint Inhibitors, Glucocorticoids, Kidney Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The impact of glucocorticoid administration for adverse events (AEs), including immune-related AEs, on the effectiveness of immune checkpoint inhibitor (ICI) combination therapy for advanced renal cell carcinoma (RCC) remains unknown. OBJECTIVES: To clarify the prognostic impact of glucocorticoid use for AEs during first-line ICI combination therapy for advanced RCC. PATIENTS AND METHODS: We retrospectively evaluated data from 194 patients who received dual ICI combination therapy [i.e., immunotherapy (IO)-IO] or combinations of ICIs with tyrosine kinase inhibitors (TKIs) as first-line therapy. The patients were divided into two groups according to the history of glucocorticoid administration in each treatment group. Survival based on glucocorticoid administration was assessed. RESULTS: A total of 101 (52.0%) and 93 (48.0%) patients received IO-IO and IO-TKI combination therapy, respectively. Glucocorticoids were administered to 46 (46%) and 22 (24%) patients in the IO-IO and IO-TKI groups, respectively. In the IO-IO group, progression-free survival (PFS) and overall survival (OS) were significantly longer in patients with glucocorticoid administration than in those without administration (median PFS: 14.4 versus 3.45 months, p = 0.0005; median OS: 77.6 versus 33.9 months, p = 0.0025). Multivariable analysis showed that glucocorticoid administration was an independent predictor of longer PFS (hazard ratio: 0.43, p = 0.0005) and OS (hazard ratio: 0.35, p = 0.0067) after adjustment for covariates. In the IO-TKI group, neither PFS nor OS significantly differed between patients treated with and without glucocorticoid administration (PFS: p = 0.0872, OS: p = 0.216). CONCLUSIONS: Glucocorticoid administration did not negatively impact the effectiveness of ICI combination therapy for RCC, prompting glucocorticoid treatment use when AEs develop.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellImmune Checkpoint InhibitorsGlucocorticoidsKidney NeoplasmsHumansMaleFemaleRetrospective StudiesAgedMiddle AgedAged, 80 and overAdult

Substanzen

Immune Checkpoint InhibitorsGlucocorticoids

Autor:innen und Institutionen

  • Department of Urology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, Japan.
  • Department of Urology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, Japan. ishihara.hiroki@twmu.ac.jp.
  • Department of Urology, Joban Hospital, 57 Kaminodai, Jobankamiyunagayamachi, Iwaki, Fukushima, Japan.
  • Department of Urology, Saiseikai Kazo Hospital, 1680 Kamitakayanagi, Kazo, Saitama, Japan.
  • Department of Urology, Saiseikai Kawaguchi General Hospital, 5-11-5 Nishikawaguchi, Kawaguchi, Saitama, Japan.
  • Department of Urology, Tokyo Women's Medical University Adachi Medical Center, 4-33-1 Kouhoku, Adachi-ku, Tokyo, Japan.

ORCID-Profile: Hiroki Ishihara

Zitieren

APA

Yoshino, M., Ishihara, H., Nemoto, Y., Mizoguchi, S., Ikeda, T., Nakayama, T., Fukuda, H., Yoshida, K., Iizuka, J., Shimmura, H., Hashimoto, Y., Kondo, T., & Takagi, T. (2024). Survival Impact of Glucocorticoid Administration for Adverse Events During Immune Checkpoint Inhibitor Combination Therapy in Patients with Previously Untreated Advanced Renal Cell Carcinoma. Targeted Oncology. https://doi.org/10.1007/s11523-024-01069-6

Vancouver

Yoshino M, Ishihara H, Nemoto Y, Mizoguchi S, Ikeda T, Nakayama T, et al. Survival Impact of Glucocorticoid Administration for Adverse Events During Immune Checkpoint Inhibitor Combination Therapy in Patients with Previously Untreated Advanced Renal Cell Carcinoma. Targeted Oncology. 2024. doi:10.1007/s11523-024-01069-6

BibTeX
@article{Yoshino2024,
  author = {Yoshino, Maki and Ishihara, Hiroki and Nemoto, Yuki and Mizoguchi, Shinsuke and Ikeda, Takashi and Nakayama, Takayuki and Fukuda, Hironori and Yoshida, Kazuhiko and Iizuka, Junpei and Shimmura, Hiroaki and Hashimoto, Yasunobu and Kondo, Tsunenori and Takagi, Toshio},
  title = {Survival Impact of Glucocorticoid Administration for Adverse Events During Immune Checkpoint Inhibitor Combination Therapy in Patients with Previously Untreated Advanced Renal Cell Carcinoma},
  journal = {Targeted Oncology},
  year = {2024},
  doi = {10.1007/s11523-024-01069-6}
}
Kostenlos starten →